Between the two industry giants, Fidelity’s robust platform pulls slightly ahead Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT).

NASHVILLE, Tenn. -- Racial biases persist in the use of pulse oximetry devices for patients with acute hypoxemic respiratory failure (AHRF) requiring very high levels of oxygen support, a ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...